非格列酮我们真的需要对 2 型糖尿病和肾脏疾病进行额外治疗吗？

IF 1.7 4区医学 Q3 MEDICINE, GENERAL & INTERNAL British journal of hospital medicine Pub Date : 2025-01-24 Epub Date: 2025-01-20 DOI:10.12968/hmed.2024.0715

Deepika Manoharan, Nicholas Gangoo, William Hinchliffe

{"title":"非格列酮我们真的需要对 2 型糖尿病和肾脏疾病进行额外治疗吗？","authors":"Deepika Manoharan, Nicholas Gangoo, William Hinchliffe","doi":"10.12968/hmed.2024.0715","DOIUrl":null,"url":null,"abstract":"Patients with chronic kidney disease (CKD) and type 2 diabetes mellitus (T2DM) face considerable cardiorenal morbidity and mortality despite existing therapies. Recent clinical trials demonstrate the efficacy of finerenone, a novel non-steroidal mineralocorticoid receptor antagonist, in reducing adverse renal and cardiovascular outcomes. This editorial briefly reviews the evidence and its implications for clinical practice, advocating the use of finerenone in these high-risk patients in combination with currently established treatment agents.","PeriodicalId":9256,"journal":{"name":"British journal of hospital medicine","volume":"86 1","pages":"1-7"},"PeriodicalIF":1.7000,"publicationDate":"2025-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Finerenone: Do We Really Need an Additional Therapy in Type 2 Diabetes Mellitus and Kidney Disease?\",\"authors\":\"Deepika Manoharan, Nicholas Gangoo, William Hinchliffe\",\"doi\":\"10.12968/hmed.2024.0715\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Patients with chronic kidney disease (CKD) and type 2 diabetes mellitus (T2DM) face considerable cardiorenal morbidity and mortality despite existing therapies. Recent clinical trials demonstrate the efficacy of finerenone, a novel non-steroidal mineralocorticoid receptor antagonist, in reducing adverse renal and cardiovascular outcomes. This editorial briefly reviews the evidence and its implications for clinical practice, advocating the use of finerenone in these high-risk patients in combination with currently established treatment agents.\",\"PeriodicalId\":9256,\"journal\":{\"name\":\"British journal of hospital medicine\",\"volume\":\"86 1\",\"pages\":\"1-7\"},\"PeriodicalIF\":1.7000,\"publicationDate\":\"2025-01-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"British journal of hospital medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.12968/hmed.2024.0715\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/20 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"British journal of hospital medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.12968/hmed.2024.0715","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/20 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

摘要

尽管已有治疗方法，慢性肾脏疾病（CKD）和2型糖尿病（T2DM）患者仍面临相当大的心肾发病率和死亡率。最近的临床试验表明，芬尼酮是一种新型的非甾体矿物皮质激素受体拮抗剂，在减少肾脏和心血管不良后果方面具有疗效。这篇社论简要回顾了证据及其对临床实践的影响，提倡在这些高风险患者中联合使用芬尼酮和现有的治疗药物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Finerenone: Do We Really Need an Additional Therapy in Type 2 Diabetes Mellitus and Kidney Disease?

Patients with chronic kidney disease (CKD) and type 2 diabetes mellitus (T2DM) face considerable cardiorenal morbidity and mortality despite existing therapies. Recent clinical trials demonstrate the efficacy of finerenone, a novel non-steroidal mineralocorticoid receptor antagonist, in reducing adverse renal and cardiovascular outcomes. This editorial briefly reviews the evidence and its implications for clinical practice, advocating the use of finerenone in these high-risk patients in combination with currently established treatment agents.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

British journal of hospital medicine 医学-医学：内科

CiteScore

1.50

自引率

0.00%

发文量

176

审稿时长

4-8 weeks

期刊介绍： British Journal of Hospital Medicine was established in 1966, and is still true to its origins: a monthly, peer-reviewed, multidisciplinary review journal for hospital doctors and doctors in training. The journal publishes an authoritative mix of clinical reviews, education and training updates, quality improvement projects and case reports, and book reviews from recognized leaders in the profession. The Core Training for Doctors section provides clinical information in an easily accessible format for doctors in training. British Journal of Hospital Medicine is an invaluable resource for hospital doctors at all stages of their career. The journal is indexed on Medline, CINAHL, the Sociedad Iberoamericana de Información Científica and Scopus.